Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Thierry André, MD, Saint Antoine Hospital
Videos
Nivolumab Plus Ipilimumab Yields Superior PFS vs Chemotherapy for First-Line Treatment of Metastatic Colorectal Cancer
01/23/2024
Thierry Andre, MD, discusses the first results from the CheckMate 8HW study exploring nivolumab plus chemotherapy for the first-line treatment of microsatellite instability-high, mismatch repair-deficient metastatic colorectal cancer.
Thierry Andre, MD, discusses the first results from the CheckMate 8HW study exploring nivolumab plus chemotherapy for the first-line treatment of microsatellite instability-high, mismatch repair-deficient metastatic colorectal cancer.
Thierry Andre, MD, discusses the...
01/23/2024
Oncology
Riccardo Lencioni, MD, University of Pisa School of Medicine
Videos
Addition of Durvalumab, Bevacizumab to TACE for Hepatocellular Carcinoma Improves PFS
01/23/2024
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.
Ricardo Lencioni, MD, shares results from the phase 3 EMERALD-1 study which found the addition of durvalumab and bevacizumab to TACE improved progression-free survival among patients with hepatocellular carcinoma, compared with TACE alone.
Ricardo Lencioni, MD, shares...
01/23/2024
Oncology
Anant Ramaswamy, MD, Tata Memorial Hospital
Videos
Addition of Docetaxel to FOLFOX/CAPOX Backbone Fails to Improve OS in Advanced GEJ/Gastric Cancer
01/20/2024
Anant Ramaswamy, MD, discusses results from the phase 3 DOC-GC study which explored the efficacy of docetaxel added to a FOLFOX/CAPOX backbone for patients with advanced GEJ and gastric cancers.
Anant Ramaswamy, MD, discusses results from the phase 3 DOC-GC study which explored the efficacy of docetaxel added to a FOLFOX/CAPOX backbone for patients with advanced GEJ and gastric cancers.
Anant Ramaswamy, MD, discusses...
01/20/2024
Oncology
Jeanne Tie, MBChB, MD, Peter MacCallum Cancer Centre
Videos
Circulating Tumor DNA-Guided vs Standard Management of Locally Advanced Rectal Cancer
01/20/2024
Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.
Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.
Professor Jeanne Tie, MBChB,...
01/20/2024
Oncology
Conference Coverage
Significance of ctDNA Clearance Following Adjuvant Chemotherapy Among Patients with Radically Resected Colorectal Cancer
01/20/2024
According to updated results from a substudy of the observational GALAXY study, detection of MRD via ctDNA and ctDNA dynamics in response to adjuvant chemotherapy for colorectal cancer were found to be highly prognostic of patient outcomes in...
According to updated results from a substudy of the observational GALAXY study, detection of MRD via ctDNA and ctDNA dynamics in response to adjuvant chemotherapy for colorectal cancer were found to be highly prognostic of patient outcomes in...
According to updated results...
01/20/2024
Oncology
Conference Coverage
Combining Clinical Biomarkers for Optimal Selection of First-Line Treatment in Metastatic Colorectal Cancer
01/20/2024
According to results from the phase 3 FIRE-3 study, the combination of primary tumor sidedness and liver-limited disease status may provide for the optimal selection of first-line treatment among patients with metastatic colorectal cancer.
According to results from the phase 3 FIRE-3 study, the combination of primary tumor sidedness and liver-limited disease status may provide for the optimal selection of first-line treatment among patients with metastatic colorectal cancer.
According to results from the...
01/20/2024
Oncology
Conference Coverage
Role of ctDNA to Guide Adjuvant Chemotherapy Use for Patients With Colon Cancer
01/20/2024
In the phase 2/3 COBRA study no improvement in ctDNA clearance was observed after 6 months of chemotherapy among patients with ctDNA detected following resection of stage IIA colon cancer.
In the phase 2/3 COBRA study no improvement in ctDNA clearance was observed after 6 months of chemotherapy among patients with ctDNA detected following resection of stage IIA colon cancer.
In the phase 2/3 COBRA study no...
01/20/2024
Oncology
Conference Coverage
Tinegotinib Monotherapy Shows Efficacy Among Patients With Advanced/Metastatic Cholangiocarcinoma
01/20/2024
Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...
Results from a phase 2 study found tinegotinib monotherapy demonstrated promising clinical efficacy and tolerable safety among patients with advanced/metastatic cholangiocarcinoma previously treated with an FGFR inhibitor and patients with...
Results from a phase 2 study...
01/20/2024
Oncology
Ethan Ludmir, MD, MD Anderson Cancer Center
Videos
Adding Metastasis-Directed Therapy for Oligometastatic Pancreas Cancer
01/19/2024
Ethan Ludmir, MD, discusses results from the phase 2 EXTEND study, evaluating the addition of metastasis-directed therapy for oligometastatic pancreas cancer.
Ethan Ludmir, MD, discusses results from the phase 2 EXTEND study, evaluating the addition of metastasis-directed therapy for oligometastatic pancreas cancer.
Ethan Ludmir, MD, discusses...
01/19/2024
Oncology
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center
Videos
Global Treatment of Gastric/GEJ Cancer with Durvalumab Plus FLOT
01/19/2024
Yelena Janjigian, MD, discussed the recent subgroup analysis from the MATTERHORN study, evaluating durvalumab plus FLOT for patients with gastric or gastroesophageal junction cancer.
Yelena Janjigian, MD, discussed the recent subgroup analysis from the MATTERHORN study, evaluating durvalumab plus FLOT for patients with gastric or gastroesophageal junction cancer.
Yelena Janjigian, MD, discussed...
01/19/2024
Oncology
Conference Coverage
Adding Durvalumab, Bevacizumab to TACE Improved Progression-Free Survival Among Patients With Unresectable Hepatocellular Carcinoma
01/19/2024
According to results from the phase 3 EMERALD-1 trial, adding durvalumab and bevacizumab to transarterial chemoembolization improved the progression-free survival among patients with hepatocellular carcinoma.
According to results from the phase 3 EMERALD-1 trial, adding durvalumab and bevacizumab to transarterial chemoembolization improved the progression-free survival among patients with hepatocellular carcinoma.
According to results from the...
01/19/2024
Oncology
Conference Coverage
Randomized Study Demonstrates Efficay of [177Lu] Lu-DOTA-TATE in First-Line Setting for Advanced Gastroenteropancreatic Neuroendocrine Tumors
01/19/2024
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis...
01/19/2024
Oncology
Conference Coverage
Atezolizumab and Bevacizumab Plus Chemotherapy Provides Modest PFS Benefit in Advanced Biliary Tract Cancer
01/19/2024
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...
First-line treatment with...
01/19/2024
Oncology
Conference Coverage
Docetaxel Added to Doublet Regimen Does Not Improve Survival in Advanced GEJ/Gastric Cancers
01/18/2024
The addition of docetaxel to a doublet regimen containing 5-fluorouracil/capecitabine and oxaliplatin demonstrated no improvement in OS among patients with advanced gastroesophageal junction (GEJ) and gastric cancers, according to a phase 3...
The addition of docetaxel to a doublet regimen containing 5-fluorouracil/capecitabine and oxaliplatin demonstrated no improvement in OS among patients with advanced gastroesophageal junction (GEJ) and gastric cancers, according to a phase 3...
The addition of docetaxel to a...
01/18/2024
Oncology
Conference Coverage
Addition of Durvalumab to FLOT Improved Response Rates Among Patients with Gastric or Gastroesophageal Junction Cancer Across All Regional Subgroups
01/18/2024
The improvement to pCR among patients with GC/GEJC with durvalumab plus FLOT seen in the MATTERHORN study was found to be consistent across all regional subgroups.
The improvement to pCR among patients with GC/GEJC with durvalumab plus FLOT seen in the MATTERHORN study was found to be consistent across all regional subgroups.
The improvement to pCR among...
01/18/2024
Oncology
Conference Coverage
Thoracoscopic Esophagectomy As Standard Treatment for Patients With Thoracic Esophageal Squamous Cell Carcinoma
01/18/2024
Thoracoscopic esophagectomy was found to be non-inferior in terms of OS to conventional esophagectomy among patients with thoracic esophageal squamous cell carcinoma.
Thoracoscopic esophagectomy was found to be non-inferior in terms of OS to conventional esophagectomy among patients with thoracic esophageal squamous cell carcinoma.
Thoracoscopic esophagectomy was...
01/18/2024
Oncology
Conference Coverage
Tiragolumab in Combination With Atezolizumab And Chemotherapy Shows Promise Among Patients With Esophageal Squamous Cell Carcinoma
01/18/2024
According to results from the phase 3 SKYSCRAPER-08, tiragolumab plus atezolizumab and chemotherapy improved the progression-free survival and overall survival among patients with esophageal squamous cell carcinoma.
According to results from the phase 3 SKYSCRAPER-08, tiragolumab plus atezolizumab and chemotherapy improved the progression-free survival and overall survival among patients with esophageal squamous cell carcinoma.
According to results from the...
01/18/2024
Oncology
Firas Baidoun, MD, Mayo Clinic - Florida
Videos
Neoadjuvant Chemotherapy Demonstrates Survival Benefit for Patients With Stage III Cholangiocarcinoma
03/06/2023
Firas Baidoun, MD, discusses an abstract presented at 2023 ASCO Gastrointestinal Cancers Symposium evaluating peri-operative chemotherapy for patients with non-metastatic cholangiocarcinoma.
Firas Baidoun, MD, discusses an abstract presented at 2023 ASCO Gastrointestinal Cancers Symposium evaluating peri-operative chemotherapy for patients with non-metastatic cholangiocarcinoma.
Firas Baidoun, MD, discusses an...
03/06/2023
Oncology
Conference Coverage
Ripretinib for Patients With Advanced GISTs in Later-Line Therapy
02/24/2023
In a multicenter, retrospective study, ripretinib demonstrated clinical activity and was well-tolerated among patients with advanced gastrointestinal stromal tumors who had previously received ≥3 lines of therapy.
In a multicenter, retrospective study, ripretinib demonstrated clinical activity and was well-tolerated among patients with advanced gastrointestinal stromal tumors who had previously received ≥3 lines of therapy.
In a multicenter, retrospective...
02/24/2023
Oncology
Conference Coverage
Ramucirumab Plus Trifluridine/Tipiracil Beyond Progression for Gastric or Gastroesophageal Junction Cancers
02/21/2023
In a single arm, phase 2 study, continuing ramucirumab in combination with trifluridine/tipiracil beyond progression demonstrated favorable safety and promising efficacy for gastric or gastroesophageal junction adenocarcinomas.
In a single arm, phase 2 study, continuing ramucirumab in combination with trifluridine/tipiracil beyond progression demonstrated favorable safety and promising efficacy for gastric or gastroesophageal junction adenocarcinomas.
In a single arm, phase 2 study,...
02/21/2023
Oncology
Sebastian Stintzing, MD, Charité — Berlin University of Medicine
Videos
Initial Cycle of Chemotherapy Does Not Influence Efficacy of First-Line FOLFIRI Plus Cetuximab for RAS Wild-Type Colorectal Cancer
02/08/2023
Sebastian Stintzing, MD, shares results from the phase 3 FIRE-4 trial showing the administration of an initial cycle of chemotherapy had no effect on the efficacy of first-line FOLFIRI plus cetuximab therapy for patients with RAS wild-type...
Sebastian Stintzing, MD, shares results from the phase 3 FIRE-4 trial showing the administration of an initial cycle of chemotherapy had no effect on the efficacy of first-line FOLFIRI plus cetuximab therapy for patients with RAS wild-type...
Sebastian Stintzing, MD, shares...
02/08/2023
Oncology
Zev Wainberg, MD, University of California - Los Angeles
Videos
First-Line NALIRIFOX Conveys Survival Benefits for Metastatic Pancreatic Ductal Adenocarcinoma
02/07/2023
Zev Wainberg, MD, reviews results from the NAPOLI-3 study, the first study since 2010 to show an overall survival advantage in pancreatic cancer.
Zev Wainberg, MD, reviews results from the NAPOLI-3 study, the first study since 2010 to show an overall survival advantage in pancreatic cancer.
Zev Wainberg, MD, reviews...
02/07/2023
Oncology
Stacey Cohen, MD, Fred Hutchinson Cancer Center
Videos
What is the Optimal Timing to Test for Circulating Tumor DNA to Detect MRD in Colorectal Cancer?
02/02/2023
Stacey Cohen, MD, reviews results from a study evaluating the optimal timing to test for circulating tumor DNA to detect MRD following surgery in patients with colorectal cancer.
Stacey Cohen, MD, reviews results from a study evaluating the optimal timing to test for circulating tumor DNA to detect MRD following surgery in patients with colorectal cancer.
Stacey Cohen, MD, reviews...
02/02/2023
Oncology
Rachna Shroff, MD, University of Arizona Cancer Center
Videos
No Survival Benefit From Addition of Nab-paclitaxel to Gemcitabine-Cisplatin for Patients With Biliary Tract Cancers
01/26/2023
Rachna Shroff, MD, shares data from a phase 3 trial evaluating gemcitabine, cisplatin, and nab-paclitaxel for newly diagnosed, advanced biliary tract cancers.
Rachna Shroff, MD, shares data from a phase 3 trial evaluating gemcitabine, cisplatin, and nab-paclitaxel for newly diagnosed, advanced biliary tract cancers.
Rachna Shroff, MD, shares data...
01/26/2023
Oncology
Josep Tabernero, MD, Vall d'Hebron Institute of Oncology
Videos
Addition of Bevacizumab to Trifluridine/Tipiracil Improves OS Among Patients with Refractory Metastatic Colorectal Cancer
01/23/2023
At the 2023 ASCO Gastrointestinal Symposium, Josep Tabernero, MD, shared results from the phase 3 trial evaluating trifluridine/tipiracil plus bevacizumab for patients with refractory colorectal cancer.
At the 2023 ASCO Gastrointestinal Symposium, Josep Tabernero, MD, shared results from the phase 3 trial evaluating trifluridine/tipiracil plus bevacizumab for patients with refractory colorectal cancer.
At the 2023 ASCO...
01/23/2023
Oncology
Conference Coverage
Botensilimab Plus Balstilimab Demonstrated Durable Responses for Patients With Microsatellite Stable Colorectal Cancer
01/21/2023
In an expanded phase 1a/1b study presented at 2023 ASCO Gastrointestinal Cancers Symposium, botensilimab plus balstilimab demonstrated durable clinical activity for patients with microsatellite stable colorectal cancer.
In an expanded phase 1a/1b study presented at 2023 ASCO Gastrointestinal Cancers Symposium, botensilimab plus balstilimab demonstrated durable clinical activity for patients with microsatellite stable colorectal cancer.
In an expanded phase 1a/1b study...
01/21/2023
Oncology
Conference Coverage
Survival Benefits From Durvalumab Not Affected by Antibiotic Use Among Patients With Biliary Tract Cancer
01/21/2023
In a study presented at 2023 ASCO Gastrointestinal Cancers Symposium, there was no difference found in the survival outcomes of patients who received antibiotics during the study evaluating durvalumab for biliary tract cancer.
In a study presented at 2023 ASCO Gastrointestinal Cancers Symposium, there was no difference found in the survival outcomes of patients who received antibiotics during the study evaluating durvalumab for biliary tract cancer.
In a study presented at 2023...
01/21/2023
Oncology
Conference Coverage
Long-Course Chemoradiation vs Short-Course Radiation Therapy for Organ Preservation Among Patients With Rectal Cancer
01/21/2023
In a study presented at 2023 ASCO Gastrointestinal Cancers Symposium, long-course chemoradiation as total neoadjuvant therapy for patients with rectal cancer was associated with a numerically higher organ preservation rate than short-course...
In a study presented at 2023 ASCO Gastrointestinal Cancers Symposium, long-course chemoradiation as total neoadjuvant therapy for patients with rectal cancer was associated with a numerically higher organ preservation rate than short-course...
In a study presented at 2023...
01/21/2023
Oncology
Laura Dawson, MD, Princess Margaret Cancer Center
Videos
Stereotactic Body Radiotherapy Plus Sorafenib Improved Survival Outcomes for Patients With Hepatocellular Carcinoma Compared to Sorafenib Alone
01/20/2023
At the 2023 ASCO Gastrointestinal Symposium, Laura Dawson, MD, shares updated data from the NRG/RTOG 1112 trial evaluating stereotactic body radiotherapy plus sorafenib compared with sorafenib for hepatocellular carcinoma.
At the 2023 ASCO Gastrointestinal Symposium, Laura Dawson, MD, shares updated data from the NRG/RTOG 1112 trial evaluating stereotactic body radiotherapy plus sorafenib compared with sorafenib for hepatocellular carcinoma.
At the 2023 ASCO...
01/20/2023
Oncology
Conference Coverage
Nanvuranlat Demonstrated Clinical Activity for Advanced, Refractory Biliary Tract Cancers
01/20/2023
According to a phase 2 trial presented at the 2023 ASCO Gastrointestinal Cancers Symposium, the LAT1-inhibitor nanvuranlat significantly improved progression-free survival for patients with advanced refractory biliary tract cancers, compared...
According to a phase 2 trial presented at the 2023 ASCO Gastrointestinal Cancers Symposium, the LAT1-inhibitor nanvuranlat significantly improved progression-free survival for patients with advanced refractory biliary tract cancers, compared...
According to a phase 2 trial...
01/20/2023
Oncology
Conference Coverage
Tislelizumab Yields Better Health-Related Quality of Life Outcomes vs Sorafenib for Patients With Unresectable Hepatocellular Carcinoma
01/20/2023
Patients with hepatocellular carcinoma treated with tislelizumab had better health-related quality of life outcomes compared to those treated with sorafenib, according to results presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
Patients with hepatocellular carcinoma treated with tislelizumab had better health-related quality of life outcomes compared to those treated with sorafenib, according to results presented at the 2023 ASCO Gastrointestinal Cancers Symposium.
Patients with hepatocellular...
01/20/2023
Oncology
Laura Dawson, MD, Princess Margaret Cancer Center
Videos
Palliative Radiotherapy Improves Pain for Patients With Symptomatic Hepatocellular Carcinoma and Liver Metastases
01/20/2023
At the 2023 ASCO Gastrointestinal Symposium, Laura Dawson, MD, shares results from a study evaluating palliative radiotherapy for hepatocellular carcinoma and liver metastases.
At the 2023 ASCO Gastrointestinal Symposium, Laura Dawson, MD, shares results from a study evaluating palliative radiotherapy for hepatocellular carcinoma and liver metastases.
At the 2023 ASCO...
01/20/2023
Oncology
Conference Coverage
Nivolumab Plus Chemotherapy Demonstrates Durable Survival Benefits for Patients With Gastric/Gastroesophageal Junction Cancer
01/20/2023
According to phase 3 trial data presented at the 2023 ASCO Gastrointestinal Cancers Symposium, nivolumab plus chemotherapy demonstrated a clinically meaningful long-term survival benefit for patients with gastric cancer, gastroesophageal...
According to phase 3 trial data presented at the 2023 ASCO Gastrointestinal Cancers Symposium, nivolumab plus chemotherapy demonstrated a clinically meaningful long-term survival benefit for patients with gastric cancer, gastroesophageal...
According to phase 3 trial data...
01/20/2023
Oncology
Conference Coverage
Active HER2 Immunization Provides Survival Benefit for Patients With HER2-Overexpressing Gastric/Gastroesophageal Junction Cancers
01/20/2023
According to a phase 2 trial presented at the 2023 ASCO Gastrointestinal Cancers Symposium, the HER2 vaccine plus chemotherapy improved overall survival compared to chemotherapy alone for patients with HER2-overexpressing...
According to a phase 2 trial presented at the 2023 ASCO Gastrointestinal Cancers Symposium, the HER2 vaccine plus chemotherapy improved overall survival compared to chemotherapy alone for patients with HER2-overexpressing...
According to a phase 2 trial...
01/20/2023
Oncology
Kohei Shitara, MD, National Cancer Center East
Videos
First-line Zolbetuximab Plus FOLFOX6 for Claudin-18.2-positive/HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
01/19/2023
At the 2023 ASCO Gastrointestinal Symposium, Kohei Shitara, MD, presents first results from a phase 3 study evaluating zolbetuximab plus modified FOLFOX6 in the first-line setting for patients with claudin-18.2-positive/HER2-negative locally...
At the 2023 ASCO Gastrointestinal Symposium, Kohei Shitara, MD, presents first results from a phase 3 study evaluating zolbetuximab plus modified FOLFOX6 in the first-line setting for patients with claudin-18.2-positive/HER2-negative locally...
At the 2023 ASCO...
01/19/2023
Oncology
Filippo Pietrantonio, MD, National Cancer Center Milan
Conference Coverage
Neoadjuvant Tremelimumab Plus Durvalumab for MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma
01/19/2023
At the 2023 ASCO Gastrointestinal Symposium, Filippo Pietrantonio, MD, discusses the phase 2 INFINITY trial of tremelimumab plus durvalumab as neoadjuvant treatment for patients with microsatellite instability high gastric/gastroesophageal...
At the 2023 ASCO Gastrointestinal Symposium, Filippo Pietrantonio, MD, discusses the phase 2 INFINITY trial of tremelimumab plus durvalumab as neoadjuvant treatment for patients with microsatellite instability high gastric/gastroesophageal...
At the 2023 ASCO...
01/19/2023
Oncology
Conference Coverage
Multimodal CROSS Regimen vs Perioperative Chemotherapy for Locally Advanced Gastroesophageal Junction Adenocarcinoma
01/19/2023
Results from a recent trial presented at the 2023 ASCO Gastrointestinal Cancers Symposium support clinical equipoise between the multimodal CROSS regimen and perioperative chemotherapy for locally advanced GEJ cancer.
Results from a recent trial presented at the 2023 ASCO Gastrointestinal Cancers Symposium support clinical equipoise between the multimodal CROSS regimen and perioperative chemotherapy for locally advanced GEJ cancer.
Results from a recent trial...
01/19/2023
Oncology
Conference Coverage
Regorafenib As a New Treatment Option for Patients With Advanced Refractory Gastroesophageal Junction Cancer
01/19/2023
According to a phase 3 trial presented at the 2023 ASCO Gastrointestinal Cancers Symposium, regorafenib improved the survival of patients with advanced refractory gastroesophageal junction cancer, compared to placebo.
According to a phase 3 trial presented at the 2023 ASCO Gastrointestinal Cancers Symposium, regorafenib improved the survival of patients with advanced refractory gastroesophageal junction cancer, compared to placebo.
According to a phase 3 trial...
01/19/2023
Oncology
Dr Harris Highlights Multi-Platform Profiling With Biospecimens in Biliary Tract Cancer
Videos
Dr Harris Highlights Multi-Platform Profiling With Biospecimens in Biliary Tract Cancer
02/08/2021
William Harris, MD, discusses a feasibility study on using biospecimen-based multi-platform profiling for patients with resected biliary tract cancer.
William Harris, MD, discusses a feasibility study on using biospecimen-based multi-platform profiling for patients with resected biliary tract cancer.
William Harris, MD, discusses a...
02/08/2021
Oncology
Dr King Highlights Progress of Ongoing Feasibility Study for Biliary Tract Cancer
Videos
Dr King Highlights Progress of Ongoing Feasibility Study for Biliary Tract Cancer
01/26/2021
Gentry King, MD, discusses an ongoing feasibility study on multiomic platform-based testing in patients with localized and resectable biliary tract cancers.
Gentry King, MD, discusses an ongoing feasibility study on multiomic platform-based testing in patients with localized and resectable biliary tract cancers.
Gentry King, MD, discusses an...
01/26/2021
Oncology
News
Axitinib Plus Octreotide Acetate Safe, Active for Grade 1/2 Gastric NETs
01/19/2021
Axitinib in combination with octreotide acetate showed activity and tolerable safety in patients with G1-G2 NETS of non-pancreatic origin.
Axitinib in combination with octreotide acetate showed activity and tolerable safety in patients with G1-G2 NETS of non-pancreatic origin.
Axitinib in combination with...
01/19/2021
Oncology
Conference Insider
Nivolumab Improves OS Versus Chemo in Advanced Esophageal Squamous Cell Carcinoma
01/16/2021
Long-term results from the ATTRACTION-3 trial show nivolumab improves survival over chemotherapy for patients with advanced esophageal squamous cell carcinoma.
Long-term results from the ATTRACTION-3 trial show nivolumab improves survival over chemotherapy for patients with advanced esophageal squamous cell carcinoma.
Long-term results from the...
01/16/2021
Oncology
Conference Insider
Anlotinib Prolongs OS in RAS, KRAS, BRAF-Wildtype Metastatic CRC
01/16/2021
Anlotinib was beneficial in Chinese patients with refractory metastatic CRC, and yielded particular OS improvement in those with RAS/KRAS/BRAF-wildtype disease.
Anlotinib was beneficial in Chinese patients with refractory metastatic CRC, and yielded particular OS improvement in those with RAS/KRAS/BRAF-wildtype disease.
Anlotinib was beneficial in...
01/16/2021
Oncology
Conference Insider
Lanreotide-Pembrolizumab Combo Stabilizes Disease in Certain Patients With GEPNETs
01/15/2021
Lanreotide combined with pembrolizumab led to stable disease with acceptable safety in nearly 40% of patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs), according to results published at the virtual 2021 ASCO GI Cancers...
Lanreotide combined with pembrolizumab led to stable disease with acceptable safety in nearly 40% of patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs), according to results published at the virtual 2021 ASCO GI Cancers...
Lanreotide combined with...
01/15/2021
Oncology
News
Surgery Plus Systemic Therapy Improves Outcomes in Stage IV GIST
01/14/2021
A study evaluating treatment methods of stage IV GIST found surgery in combination with systemic therapy demonstrates the best outcomes for patients.
A study evaluating treatment methods of stage IV GIST found surgery in combination with systemic therapy demonstrates the best outcomes for patients.
A study evaluating treatment...
01/14/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

Conference Coverage
Randomized Study Demonstrates Efficay of [177Lu] Lu-DOTA-TATE in First-Line Setting for Advanced Gastroenteropancreatic Neuroendocrine Tumors
01/19/2024
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis...
01/19/2024
Oncology
News
Axitinib Plus Octreotide Acetate Safe, Active for Grade 1/2 Gastric NETs
01/19/2021
Axitinib in combination with octreotide acetate showed activity and tolerable safety in patients with G1-G2 NETS of non-pancreatic origin.
Axitinib in combination with octreotide acetate showed activity and tolerable safety in patients with G1-G2 NETS of non-pancreatic origin.
Axitinib in combination with...
01/19/2021
Oncology
News
Surgery Plus Systemic Therapy Improves Outcomes in Stage IV GIST
01/14/2021
A study evaluating treatment methods of stage IV GIST found surgery in combination with systemic therapy demonstrates the best outcomes for patients.
A study evaluating treatment methods of stage IV GIST found surgery in combination with systemic therapy demonstrates the best outcomes for patients.
A study evaluating treatment...
01/14/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement